Breaking Down Dalian BIO-CHEM Company Limited Financial Health: Key Insights for Investors

Dalian BIO-CHEM (603360.SS) just posted a headline-grabbing CNY 1.31 billion revenue in 2024 - up 23.09% year-over-year with a five-year CAGR near 10% - fuelled by a semiconductor-equipment surge of 215.75% and Q1 2025 semiconductor sales of CNY 0.26 billion (a staggering 389.39% YoY jump); beneath that growth the picture is mixed: gross margin slipped to 43.75% from 51.13% even as net income rose to CNY 345.26 million (+5.14%) with a net margin of 26.32% and EBITDA margin of 24.96%, but EPS fell to CNY 0.68 (-26.9%) amid share buybacks (5,365,500 shares repurchased for CNY 111.56 million); the balance sheet shows total debt of CNY 1.12 billion, net debt of CNY 368.02 million, debt/equity 53.87% and debt/EBITDA at 3.04 against an equity base of CNY 2.08 billion (book value per share CNY 2.15), while liquidity remains solid (current ratio 2.96, quick ratio 1.45) and cash generation is positive (TTM operating cash flow CNY 122.83 million, free cash flow CNY 63.52 million, latest-quarter cash increase CNY 110.26 million) with an Altman Z‑Score of 6.68; investors face valuation and leverage questions-trailing P/E 99.28, forward P/E 57.31, P/S 15.20, P/B 10.77, EV/EBITDA 63.31 and EV/Revenue 15.84-set against risks like rising production costs, a declining ROE (TTM 12.86% vs historical 21.30%), a net‑debt position, and concentration in semiconductors, while catalysts include international expansion, a CNY 0.43 dividend (payout ratio 63%), and further semiconductor investment-read on to unpack what these figures mean for the stock and your portfolio

Dalian BIO-CHEM Company Limited (603360.SS) - Revenue Analysis

• 2024 revenue: CNY 1.31 billion (↑23.09% vs 2023)
• 5-year revenue CAGR: ~10%
• Gross profit margin 2024: 43.75% (2023: 51.13%) - margin compression due to higher production costs
• Revenue per employee (2024): ~CNY 1.54 million (implies ~851 employees)

• Semiconductor equipment revenue (2024): increased by 215.75% YoY - a major contributor to the 2024 topline jump. Example: if 2023 semiconductor equipment revenue was ~CNY 0.08 billion, 2024 rose to ~CNY 0.25 billion (215.75% growth).
• Semiconductor business Q1 2025: CNY 0.26 billion, YoY increase of 389.39% - signaling strong momentum into 2025.
• Overall revenue mix shifted toward higher-growth, higher-capital equipment sales in 2024, supporting absolute revenue growth but weighing on gross margin as production and ramp-up costs rose.

Dalian BIO-CHEM Company Limited (603360.SS) - Profitability Metrics

Key profitability indicators for Dalian BIO-CHEM Company Limited (603360.SS) show a company with solid margins and operational efficiency, though certain return metrics have softened compared with historical averages. Relevant metrics for 2024 and trailing twelve months (TTM) as of December 2025 are summarized below.

• Net income growth: 5.14% increase in 2024 vs 2023 (CNY 328.12m → CNY 345.26m).
• High conversion of revenue to profit: net profit margin at 26.32% in 2024.
• Strong operational efficiency: EBITDA margin nearly 25% and operating margin 16.26%.
• ROE compression: TTM ROE of 12.86% is materially below the historical 21.30% average, signaling lower equity returns.
• EPS decline of 26.9% in 2024 (CNY 0.68) attributed primarily to increased share repurchases affecting per-share calculations.

For broader corporate context and how these profitability metrics interact with Dalian BIO-CHEM's strategy, ownership and history, see: Dalian BIO-CHEM Company Limited: History, Ownership, Mission, How It Works & Makes Money

Dalian BIO-CHEM Company Limited (603360.SS) - Debt vs. Equity Structure

Key balance-sheet and leverage metrics for Dalian BIO-CHEM Company Limited (603360.SS) highlight a company with moderate financial leverage but pockets of risk when measured against cash generation. Below are the most relevant figures from the latest quarter and concise context for investors.

• Total leverage is moderate: at 53.87% debt-to-equity, debt is just over half of book equity, leaving equity as the larger claim on assets.
• Net debt of CNY 368.02 million means the company is not in a net-cash position; debt servicing depends on continued cash generation.
• Debt-to-EBITDA of 3.04x suggests manageable leverage for now but sensitivity to EBITDA declines.
• Interest coverage of 12.50x provides a cushion against rising rates or temporary earnings weakness.
• Debt-to-free cash flow at 17.63x is a warning sign: free cash flow is relatively small versus total debt, increasing refinancing or liquidity risk.

For further reading on ownership and investor interest that may affect access to capital and strategic direction, see: Exploring Dalian BIO-CHEM Company Limited Investor Profile: Who's Buying and Why?

Dalian BIO-CHEM Company Limited (603360.SS) - Liquidity and Solvency

• Current ratio: 2.96 - strong ability to cover short-term liabilities with short-term assets.
• Quick ratio: 1.45 - sufficient liquidity to meet immediate obligations without relying on inventory.
• Operating cash flow (TTM): CNY 122.83 million - solid cash generation from core operations.
• Free cash flow (TTM): CNY 63.52 million - positive cash flow after capital expenditures.
• Net change in cash (latest quarter): CNY 110.26 million - increase in cash reserves in the most recent quarter.
• Altman Z-Score: 6.68 - indicates very low bankruptcy risk and strong financial health.

• Implication for creditors: Low short-term default risk given strong coverage ratios and cash buffers.
• Implication for equity investors: Cash generation and positive free cash flow support dividend potential, buybacks, or reinvestment.
• Potential watch items: Monitor inventory turnover and capex trends to ensure quick ratio and FCF sustainability.

Dalian BIO-CHEM Company Limited (603360.SS) - Valuation Analysis

Dalian BIO-CHEM Company Limited (603360.SS) presents valuation multiples that indicate a premium market pricing relative to current fundamentals, with expectations of earnings improvement reflected in forward measures.

• Valuation premium drivers: anticipated margin expansion, pipeline or product mix improvements, and investor appetite for specialty chemical/biotech exposure.
• Market sensitivity: high multiples increase downside risk if growth disappoints or macro conditions worsen.
• Relative comparison note: multiples (P/E ~99, EV/EBITDA ~63) are well above typical industrial/chemical sector medians (often P/E 10-25, EV/EBITDA 6-15), implying a stretched valuation.

Key considerations for investors include earnings visibility, capital expenditure needs, and how much of the premium reflects temporary investor sentiment versus durable competitive advantages. For profile and ownership context see Exploring Dalian BIO-CHEM Company Limited Investor Profile: Who's Buying and Why?

Dalian BIO-CHEM Company Limited (603360.SS) - Risk Factors

Dalian BIO-CHEM Company Limited (603360.SS) presents several financial and operational risks that investors should weigh carefully. Below are the principal risk drivers, supported by the latest available figures and their potential implications.

• Net debt position: CNY 368.02 million - increases sensitivity to interest-rate movements and refinancing risk; higher leverage can constrain capital allocation and dividend capacity.
• Gross profit margin decline: from 51.13% to 43.75% year-over-year - indicates rising production or input costs and/or pricing pressure that compresses operating leverage.
• Return on equity (ROE) drop: from 21.30% to 12.86% year-over-year - signals reduced efficiency in generating profits from shareholders' equity and possible margin or asset-utilization deterioration.
• Concentration risk: semiconductor business revenue surged 389.39% in Q1 2025 - while strong growth, this may reflect overreliance on one segment and increases vulnerability to semiconductor-cycle swings.
• Valuation risk: trailing P/E ratio at 99.28 - suggests the market is pricing very high growth expectations; any earnings disappointment could trigger significant share-price volatility.
• Debt-to-free-cash-flow ratio: 17.63 - implies heavy reliance on debt relative to cash generation, heightening liquidity and solvency risk if cash flows weaken.

Key practical considerations for investors:

• Liquidity & covenant monitoring: watch short-term maturities, interest coverage and any debt covenants given net debt and high debt/FCF.
• Margin drivers: investigate raw-material, labor, energy and logistics cost trends as causes of the gross margin decline and monitor management's margin-recovery plans.
• Segment exposure: assess sustainability of semiconductor revenue growth, customer concentration, contractual terms and potential margin differentials vs. legacy segments.
• Valuation vigilance: with a P/E near 100x, require clear visibility on earnings trajectory and stress-test scenarios for EPS downside.
• Cash-generation sensitivity: model free-cash-flow under weaker demand to evaluate solvency pressure from a debt/FCF ratio of 17.63.

For broader context on the company's background, ownership and strategic positioning, see: Dalian BIO-CHEM Company Limited: History, Ownership, Mission, How It Works & Makes Money

Dalian BIO-CHEM Company Limited (603360.SS) - Growth Opportunities

• Semiconductor business expansion: Q1 2025 semiconductor revenue grew 389.39% year-on-year, evidencing rapid top-line acceleration in a strategic segment.
• Diversification success: Revenue from semiconductor equipment increased 215.75% year-on-year in 2024, supporting a transition from legacy products toward higher-growth, tech-driven offerings.
• Share repurchase program: The company repurchased 5,365,500 shares at a total cost of CNY 111.56 million, a move that can enhance EPS and signal management confidence in intrinsic value.
• Shareholder returns: Dividend per share is CNY 0.43 with a payout ratio of 63%, reflecting a balanced policy of returning cash while retaining capacity for reinvestment.
• International expansion: Active efforts to grow presence across Europe, the Americas and Asia create addressable-market expansion and revenue diversification opportunities.
• R&D and capex upside: Further investments in semiconductor technology and equipment could sustain above-market growth and open recurring-service and aftermarket revenue streams.

• Strategic implications for investors:
  • High semiconductor growth supports re-rating potential if margin and cash-conversion trends continue.
  • Repurchases and a 63% payout ratio indicate management alignment with shareholder returns while maintaining reinvestment capacity.
  • Geographic expansion reduces single-market dependency and raises upside from global semiconductor spend cycles.